Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
ImpactNotable 30/100
Why it mattersRule-based estimate: no strong signals; trust 7/10.
RegionsGlobal
Published4 h ago (Fri, 02 Oct 2026 15:20:29 GMT)
RetrievedFri, 02 Oct 2026 17:00:26 GMT via rss
ClassifiedFri, 02 Oct 2026 17:00:39 GMT by heuristic